Impacts of tumor microenvironment during neoadjuvant chemotherapy in patients with esophageal squamous cell carcinoma

被引:2
|
作者
Sugawara, Kotaro [1 ]
Fukuda, Takashi [1 ]
Murakami, Chiaki [2 ,3 ]
Oka, Daiji [1 ]
Yoshii, Takako [4 ]
Amori, Gulanbar [2 ,5 ,6 ]
Ishibashi, Kumiko [2 ]
Kobayashi, Yasuhito [2 ]
Hara, Hiroki [4 ]
Kanda, Hiroaki [2 ]
Motoi, Noriko [2 ,7 ]
机构
[1] Saitama Canc Ctr, Dept Gastroenterol Surg, Saitama, Japan
[2] Saitama Canc Ctr, Dept Pathol, 780 Komuro, Ina, Saitama 3620806, Japan
[3] Saitama Med Univ, Saitama Med Ctr, Dept Pathol, Saitama, Japan
[4] Saitama Canc Ctr, Dept Gastroenterol, Saitama, Japan
[5] Japanese Fdn Canc Res, Canc Inst, Div Pathol, Tokyo, Japan
[6] Japanese Fdn Canc Res, Canc Inst Hosp JFCR, Dept Pathol, Tokyo, Japan
[7] Saitama Canc Ctr, Ctr Canc Genom Med, Saitama, Japan
关键词
esophageal squamous cell carcinoma; immune checkpoint inhibitor; neoadjuvant chemotherapy; surgery; tumor microenvironment; INFILTRATING LYMPHOCYTES; CANCER; EXPRESSION; SURVIVAL; THERAPY;
D O I
10.1111/cas.16203
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
With the advent of immune checkpoint inhibitors (ICIs), a better understanding of tumor microenvironment (TME) is becoming crucial in managing esophageal squamous cell carcinoma (ESCC) patients. We investigated the survival impact of TME status and changes in patients with ESCC who underwent neoadjuvant chemotherapy (NAC) followed by surgery (n = 264). We examined immunohistochemical status (CD4+, CD8+, CD20+, Foxp3+, HLA class-1+, CD204+, and programmed death ligand-1 [PD-L1+]) on 264 pre-NAC and 204 paired post-NAC specimens. Patients were classified by their pre- and post-NAC immune cell status and their changes following NAC. Our findings showed that pre-NAC TME status was not significantly associated with survival outcomes. In contrast, post-NAC TME status, such as low level of T cells, CD4+ T cells, and high PD-L1 combined positive score (CPS), were significantly associated with poor overall survival (OS). Notably, TME changes through NAC exerted significant survival impacts; patients with consistently low levels of T cells, low levels of CD4+ T cells, or high levels of PD-L1 (CPS) had very poor OS (3-year OS: 35.5%, 40.2%, and 33.3%, respectively). Tumor microenvironment changes of consistently low T cells, low CD4+ T cells, and high PD-L1 were independent predictors of poor OS in multivariate Cox hazards analyses, while factors indicating post-NAC status (T cells, CD4+, and PD-L1 [CPS]) alone were not. Therefore, we suggest that the consistently low T/high PD-L1 group could benefit from additional therapies, such as ICIs, and the importance of stratification by the TME, which has recently been recognized. Tumor microenvironment after neoadjuvant chemotherapy (NAC), such as low T cells, low CD4+ cells, or high programmed death ligand-1 [PD-L1], were significantly associated with poor survival in patients with esophageal squamous cell carcinoma. Importantly, immune cell changes following NAC, such as consistently low T cells, consistently low CD4+ cells, or persistently high PD-L1, were independent predictors for poor survival.image
引用
收藏
页码:2819 / 2830
页数:12
相关论文
共 50 条
  • [31] Clinical value of hematologic test in predicting tumor response to neoadjuvant chemotherapy with esophageal squamous cell carcinoma
    Liu, Yinan
    Chen, Jinfeng
    Shao, Ningsheng
    Feng, Yuan
    Wang, Yuzhao
    Zhang, Lijian
    [J]. WORLD JOURNAL OF SURGICAL ONCOLOGY, 2014, 12
  • [32] Clinical value of hematologic test in predicting tumor response to neoadjuvant chemotherapy with esophageal squamous cell carcinoma
    Yinan Liu
    Jinfeng Chen
    Ningsheng Shao
    Yuan Feng
    Yuzhao Wang
    Lijian Zhang
    [J]. World Journal of Surgical Oncology, 12
  • [33] Impact of tumor-infiltrating dendritic cells in esophageal squamous cell carcinoma treated with neoadjuvant chemotherapy
    Nishimura, Junya
    Tanaka, Hiroaki
    Yamakoshi, Yoshihito
    Hiramatsu, Soichiro
    Tamura, Tatsuro
    Toyokawa, Takahiro
    Muguruma, Kazuya
    Hirakawa, Kosei
    Ohira, Masaichi
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [34] The Role of Adjuvant Chemotherapy in the Treatment of Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemotherapy
    Li, Keting
    Hao, Wentao
    Liu, Xianben
    Li, Yin
    Sun, Haibo
    Liu, Shilei
    Xing, Wenqun
    Zheng, Yan
    [J]. JOURNAL OF CANCER, 2023, 14 (16): : 3130 - 3138
  • [35] Neoadjuvant chemoradiotherapy versus chemotherapy and surgery for patients with locally advanced esophageal squamous cell carcinoma
    Hao, Daxuan
    Li, Xue
    Yang, Yuanyuan
    Zhang, Yougai
    Wu, Xiaoyuan
    Chen, Yongshun
    Wang, Jianhua
    [J]. TRANSLATIONAL CANCER RESEARCH, 2017, 6 (02) : 346 - 353
  • [36] Neoadjuvant chemoradiotherapy versus chemotherapy and surgery for patients with locally advanced esophageal squamous cell carcinoma
    Hao, Daxuan
    Li, Xue
    Yang, Yuanyuan
    Zhang, Yougai
    Wu, Xiaoyuan
    Chen, Yongshun
    He, Chunyu
    Wang, Wen
    Liu, Jinsong
    Wang, Jianhua
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [37] Neoadjuvant chemotherapy may not benefit esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy
    Chen, Ming-Qiu
    Lin, Qing-Liang
    Chen, Yuan-Gui
    Guo, Jin-Hua
    Xu, Ben-Hua
    Tian, Ye
    [J]. JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2017, 80 (10) : 636 - 643
  • [38] Prognostic Factors for Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Followed by Surgery
    Kitasaki, Nao
    Hamai, Yoichi
    Emi, Manabu
    Kurokawa, Tomoaki
    Yoshikawa, Toru
    Hirohata, Ryosuke
    Ohsawa, Manato
    Okada, Morithito
    [J]. IN VIVO, 2022, 36 (06): : 2852 - 2860
  • [39] Roles of circRNA dysregulation in esophageal squamous cell carcinoma tumor microenvironment
    Li, Jingyi
    Song, Yuxia
    Cai, Huihong
    Zhou, Bo
    Ma, Jun
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [40] The Role of Tumor Microenvironment in Invasion and Metastasis of Esophageal Squamous Cell Carcinoma
    Zheng, Shuyue
    Liu, Beilei
    Guan, Xinyuan
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12